Conference Details - Exhibitors

View all Conferences

Continuing Education Information

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 23.25 AMA PRA Category 1 Credits™ (up to 17.25  for the main conference, 5 for the Minisymposium, and 1 for the Poster Viewing session). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.

27th Annual Miami Breast Cancer Conference™

Fontainebleau Miami Beach Hotel
Miami, FL
March 3-6, 2010

2010 Exhibits
Exhibits are located in Sparkle West and Luster Gallerie just outside the plenary session held in Sparkle East. Breakfast and refreshment breaks will also be held in this location. Please stop by to visit our exhibitors and thank them for their support. Without them, we could not offer the quality education you enjoy at the 27th Annual Miami Breast Cancer Conference.

Abraxis Oncology
Abraxis BioScience is a fully integrated biotechnology company dedicated to delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer.

Agendia
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized therapy within reach of cancer patients.  Leveraging advancements in microarray-based technology for tumor gene expression profiling, the company's tests aim to enable physicians to more accurately tailor cancer treatment.  Agendia's MammaPrint is the first and only FDA-cleared IVDMIA gene expression assay for breast cancer recurrence. The 70 gene signature was developed on an untreated patient population using an unbiased gene selection process and provides clinicians a reliable means to identify women who are either at low risk or at high risk of distant recurrence after surgery. When used in conjunction with other clinical factors, MammaPrint can help determine if a patient may be safely treated with hormonal therapy alone, or if the addition of chemotherapy will be of benefit.  Submitting patient samples in the United States is simple and easy using the RNARetain room temperature, molecular fixative. Agendia’s CLIA certified and CAP registered laboratories are based in Huntington Beach, California, and in Amsterdam, The Netherlands.  For more information, please visit agendia.com.

AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. 

For more information visit astrazeneca-us.com.

Aurora Imaging Technology, Inc.
Aurora Imaging Technology, Inc. is committed to the fight against breast disease and is proud to manufacture the Aurora® 1.5T Dedicated Breast MRI System with Bilateral 3-D SpiralRODEO™. The Aurora Breast MRI System is the only FDA cleared, truly dedicated and truly integrated MRI system designed specifically for breast imaging.

The new AuroraEDGE™ technology radically improves image resolution and eliminates common breast MRI artifacts for crystal clear images of both breasts, axillae, chest wall and mediastinum in a single, 3-D bilateral scan. The unique pulse sequence and image acquisition system used in AuroraEDGE technology minimizes the effect of common cardiac motion on the images. The new acquisition efficiency of AuroraEDGE is used to oversample for a larger field-of-view to avoid aliasing.

AuroraEDGE Image Specifications:
• 3-D Image Resolution 512x512, 250 slices
• 0.7 mm slice thickness, no gap between slices
• Offers isotropic true 0.7mm resolution in all 3 planes
• Post-contrast time points obtained at 90-seconds, 4.5-minutes, 7.5-minutes, and 10.5-minutes

In partnership with the nation's finest breast care centers, Aurora Imaging Technology, Inc. is dedicated to providing superior diagnostic imaging tools for physicians and their patients.

Bard Biopsy
Bard is the world leader in biopsy innovations.  Bard’s newest innovation, the Finesse™ Ultra Breast Biopsy System, is the only self-contained, vacuum-assisted, ultrasound-guided breast biopsy system with SIMS Technology – the ability to acquire multiple samples with a single probe insertion.   With sampling cycle time just 10 seconds, the FinesseTM Ultra Breast Biopsy System acquires large, high-quality, contiguous tissue samples rapidly from a single insertion.  Its ultra sharp cutting tip and optional piercing mode penetrates dense breast tissue and lesions accurately without displacing the lesion.  The detachable integrated coaxial cannula can remain in the breast to maintain a track to the biopsy site to accurately place a breast tissue marker.  The Finesse™ Ultra Breast Biopsy System provides compassionate control of the patient experience, confident control of sample quality, and efficient control of the biopsy procedure.

Bard’s Vacora® Breast vacuum-assisted breast biopsy system obtains large, high-quality, contiguous tissue samples under ultrasound, stereotactic x-ray and MR image guidance.  Vacora® Biopsy System probes are available in convenient 10 gauge and 14 gauge sizes with and without a fully integrated coaxial with depth stop for consistent needle positioning and accurate marker placement.

The new UltraClip® Dual Trigger Breast Tissue Marker is simple to operate and provides exceptional control.  A choice of a front trigger and an alternate rear trigger accommodate user preference, and its ergonomic design provides a comfortable non-slip grip.  The UltraClip® Dual Trigger Breast Tissue Marker is designed to be deployed through the integrated coaxial of the Finesse™ Ultra Breast Biopsy System and Vacora® Breast Biopsy System.  The markers are available in three unique shapes with permanent ultrasound enhancement.

Bard also offers localization wires, as well as core needle biopsy systems for lung, liver, breast and prostate biopsies.

Bayer Healthcare/Onyx Pharmaceuticals
Visit us at Table 11 for more information.

Biopsy Sciences
Biopsy Sciences® is proud to introduce the HydroMARK® breast biopsy site marker developed by John Fisher MD, a breast Radiologist.  It’s the only breast marker that is made of 90% water, has less than 2mm of migration, marks the exact biopsy location, and does not contain collagen (which has known allergies).  Because it’s 90% water, it enables physicians to clearly visualize the marker under ultrasound imaging for 6 or more weeks following deployment.  Once deployed in the biopsy cavity the HydroMARK® absorbs the surrounding fluid, swells in length and diameter, and anchors in the cavity. The HydroMARK® will allow for ultrasound needle localizations.  Ultrasound needle localizations are faster, less painful, and compression free.  The HydroMARK® contains a central titanium or stainless steel metal marker for permanent visibility under mammography.  HydroMARK® has recently received the CE Mark for distribution in 27 countries of the European Union.

Website: biopsysciences.com

Bioptics
Based in Tucson, Arizona, Bioptics, Inc. was founded in 2001and has developed FDA cleared state of the art digital specimen radiography products for imaging of both surgical and core biopsies.  200 systems have been installed globally and dramatically improve efficiency by providing full PACS networking, allowing surgeons, radiologists, and pathologists the opportunity to digitally analyze breast tissue on a real-time basis while the patient is on the operating table.  In addition, Bioptics is pioneering efforts in the Small Field Digital Mammography (SFDM) and Full Field Digital Mammography (FFDM) segments with its development of SFDM and FFDM sensors for upgrading analog mammography systems. Utilizing its unique CMOS technology, Bioptics' goal is to provide the highest performance and best value solutions to its customers globally.

Bristol-Myers Squibb Company
Bristol-Myers Squibb welcomes you to Miami.  We invite you to visit our exhibit and learn of the products and services Bristol-Myers Squibb has to offer to your specialty.

Cancer Information Group
For more than ten years, CIG Media Group has been the medical publisher dedicated to peer-reviewed, tumor-specific oncology/hematology journals for clinical/medical oncologists and hematologists. CIG journals provide quality content focused on topics that affect oncologists and their patients. CIG Media Group also published proceedings from meetings in the oncology/hematology field. cigjournals.com

Carl Zeiss Radiotherapy
The Zeiss INTRABEAM System offers the least disruptive treatment method available to patients being treated for early stage breast cancer. The radiation dose is administered to the tumor bed in the operating room, following lumpectomy. This system utilizes the miniature X-ray source, a highly stable support stand and a full range of applicator options.   Simple, convenient, and reliable.

Cianna Medical       
Cianna Medical, Inc. manufactures and markets the SAVI™ breast brachytherapy applicator which allows physicians to selectively radiate tissue at greatest risk for recurrence while reducing exposure of healthy tissue. This ability to sculpt the radiation dose allows physicians to treat patients who otherwise would have been eliminated as candidates for APBI.

Elsevier Inc.
Elsevier is the leading international publisher of medical journals, books, and electronic products.

EMD Serono
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. EMD Serono has more than 1000 employees around the country and fully integrated commercial, clinical and research operations in Massachusetts.

Ethicon Endo-Surgery, Inc.
Ethicon Endo-Surgery, Inc. features the Mammotome® Biopsy System, a minimally invasive biopsy device used for partial or complete removal of imaged evidence of both palpable and non-palpable breast lesions. The Mammotome® EX, used under ultrasound guidance, now enables doctors to manage benign lesions such as fibroadenomas without the need for open surgery. The Mammotome® ST utilizes the same unique technology, but is used during those breast biopsies requiring x-ray guidance. The Mammotome® MR is used in MRI-guided breast biopsy procedures. Please visit the EES booth to take a closer look. Then visit breastcareinfo.com or call 1-800-USE-ENDO.

Faxitron X-Ray LLC
Faxitron X-Ray LLC is featuring a new digital core specimen radiography system. Named the DX-50 Core™, the unit features a new, higher-resolution camera and is intended for dedicated use in the stereotactic suite. The compact unit produces high-resolution digital images in seconds that can be viewed immediately on its flat panel display to ensure that core specimens contain a representative sample of microcalcifications. For more information contact Brad Jackson, VP Sales & Marketing, Faxitron X-Ray LLC, 575 Bond Street, Lincolnshire, IL 60069, 1-847-276-3427, faxitron.com.

Florida Breast Cancer Foundation
Florida Breast Cancer Foundation (FBCF) is a 501 (c) (3) grassroots organization with the mission to end breast cancer through advocacy, education, and research.  FBCF works statewide to raise awareness and mobilize Floridians to ensure sufficient public funding for breast cancer research, quality health care for all without fear of discrimination, and an environment free of carcinogens.  FBCF is the only organization in the State of Florida with the End Breast Cancer license plate.  All monies raised stay in the State of Florida to support advocacy, education, and research programs for Florida residents and institutions. 

Gamma Medica Ideas
Gamma Medica-Ideas (GMI) is a world leader in advanced medical imaging. For improved patient care, GMI offers Lumagem®, a dual-headed Molecular Breast Imaging system for secondary diagnosis of breast cancer. The all digital, all solid state imaging technology in Lumagem offers significant advances in resolution and contrast for identification of down to 2mm breast cancers missed by mammography. Visit gm-ideas.com.

Genentech BioOncology
At Genentech BioOncology™, we’re fundamentally transforming the way cancer is treated, with the goal of moving cancer toward a more manageable disease. Our commitment to this goal has enabled us to make significant contributions to the understanding of cancer and to translate this understanding into targeted, biologic‐based therapies.

Genomic Health, Inc.
Genomic Health, Inc. conducts sophisticated genomic research to develop clinically validated oncology molecular diagnostics, which provide individualized information on the likelihood of disease recurrence and response to certain types of therapy. These diagnostic tests generate information that physicians and patients are using to make personalized treatment decisions.

Genoptix
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists.

Our highly trained hematopathologists employ sophisticated diagnostic technologies to provide a differentiated, specialized, and integrated assessment of a patient’s condition, aiding physicians in making vital decisions concerning the treatment of malignancies of the blood and bone marrow and other forms of cancer.

GlaxoSmithKline
GlaxoSmithKline is a leading research-based pharmaceutical company with a powerful combination of skills to discover and deliver innovative medicines.  We offer a number of programs to support effective health management strategies and improve patient care.

Please visit our exhibit to learn more about our products.

Hologic, Inc.

Hologic is leading the way in women’s imaging and intervention technology. Our technologies provide clinicians with fast, effective and accurate biopsy solutions. Our systems are designed for use across all three imaging modalities: stereotactic, ultrasound and MRI. We also support your patients with a breakthrough treatment option, MammoSite, a 5-day targeted radiation therapy. Learn more about our comprehensive intervention and treatment solutions by visiting our exhibit at the Miami Breast Cancer Conference or by visiting hologic.com.

ImpediMed, Inc.
Prospectively manage Lymphedema after breast cancer.  FDA cleared, clinically validated technology detects specifically extracellular fluid.  Compliments new NIH paradigm of pre-surgical baseline and post-surgical surveillance enabling early identification and successful treatment using conservative, cost-effect measures.  Detect subclinical changes before visible swelling when intervention can return patient to pre-surgical baseline. Rapid, objective, standardized L-Dex™ device with tracking software.

Lilly Oncology
For more than four decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Our quest is to develop a broad portfolio of tailored therapies that accelerate the pace and progress of cancer care. To learn more about Lilly Oncology’s commitment to cancer, please visit LillyOncology.com.

Lippincott, Williams & Wilkins
Lippincott-Williams & Wilkins, one of the leaders in Oncology text and journal publishing.  We will be displaying several new titles at this years meeting. I hope to get a chance to meet with everyone to display our products.
Thank You,
Dale Shaughnessy
Lippincott Williams & Wilkins

Monogram Biosciences
A pioneer in individualized medicine, Monogram continues to grow into new areas of healthcare diagnostics. We have now extended our well-respected scientific innovations into the oncology arena. Our broadly applicable VeraTag™ oncology assays are designed to help physicians better determine whether certain therapies are appropriate for individual cancer patients, and whether to combine therapies.

Monogram’s HERmark® Breast Cancer Assay, based on our VeraTag technology, has been validated as an accurate, precise, reproducible assay measuring the levels of HER2 total protein and HER2 homodimers. With more accurate and quantitative results than HER2 status by conventional methods, HERmark allows physicians to make more optimal therapeutic decisions when defining the best course of treatment for patients with breast cancer. hermarkassay.com

Myriad Genetic Laboratories
Myriad Genetic Laboratories offers the BRACAnalysis® family of sequence analysis services for genetic susceptibility to breast and ovarian cancer.  Myriad is the only reference laboratory offering comprehensive sequencing of BRCA1 and BRCA2.A leader in gene research and discovery, Myriad is committed to providing educational support programs for both physicians and patients. Visit our booth to learn more about this important resource for assessing breast and ovarian cancer risk.

National Accreditation Program for Breast Centers

The National Accreditation Program for Breast Centers is a consortium of national, professional organizations dedicated to the improvement of the quality of care and the monitoring of outcomes for patients with diseases of the breast.  This multidisciplinary group defined 27 program standards and 17 program components of care that collectively define the most efficient and contemporary care available.

NeoMatrix
The HALO Breast Pap Test gives doctors and patients a new method to monitor breast cancer risk, quickly and easily. All women are at risk for developing breast cancer. Unfortunately, by the time a woman can actually feel the lump, the disease is no longer in its earliest, most treatable stage.

Novartis Oncology

Novartis Oncology delivers innovative therapies that change the way patients live with cancer and blood disorders. These include Gleevec® (imatinib mesylate) tablets, Afinitor® (everolimus) tablets, Zometa® (zoledronic acid), Femara® (letrozole tablets), Sandostatin LAR® Depot (octreotide acetate for injectable suspension) and Exjade® (deferasirox). Novartis Oncology has a robust pipeline that utilizes recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.

Novian Health
Novian Health (the Company) is a Chicago-based, privately held company with proprietary technology for the treatment of breast tumors using Interstitial Laser Therapy (ILT).  The Company has developed, tested, and patented a minimally invasive procedure, Novilase™ Breast Therapy, which uses ILT (controlled heating) for the ablation of breast tumors as an alternative to the surgically invasive standard of care, lumpectomy.  FDA clearance has been received for treatment of fibroadenomas (benign tumors) based on a 70-procedure trial with no serious adverse events, and the Company anticipates a multi-center malignant trial in 2010.

Peak Surgical
PEAK Surgical, Inc. presents the PEAK PlasmaBlades, a family of devices that cut as precisely as a scalpel and control bleeding as effectively as traditional electrosurgery without extensive collateral thermal damage.  This reduced thermal damage has been shown to result in improved surgical incision healing and patient outcomes.

Pfizer Inc.
Please visit the Pfizer Inc. US Pharmaceuticals exhibit featuring Aromasin® (exemestane).

Physicians’ Education Resource
Physicians' Education Resource (PER) is a continuing medical education company specializing in oncology and hematology. Since 1996, PER has coordinated and implemented superior educational opportunities that enable health care professionals to remain current and responsive to advances in medical care for cancer patients, from diagnosis through treatment. Find conference registration and online CME anytime at cancerlearning.com.

Sanarus Technologies
The NEW Sanarus Technologies, LLC is a leading developer of minimally invasive medical devices for diagnosing and treating breast disease.  Using innovative cryotechnology, the Cassi2 Rotational Core Biopsy Device and the Visica2 Treatment System offer women alternatives to surgical excision.  From diagnosis to treatment, cryotechnology enhances your practice – visit Booth # 19.

sanofi-aventis U.S.
sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients.  Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).  For more information, visit: sanofi-aventis.us or sanofi-aventis.com

The Ultrasound Store
The Ultrasound Store is a BBB A+ Reliability Rated Company that was selected by MD Anderson Cancer Center’s Department of Surgical Oncology, Breast Section, to install for them breast ultrasound equipment and to teach for them in Houston our Surgeon Breast Ultrasound Course as part of the installation. We now make our same, comprehensive course, also taught at Mt. Sinai School of Medicine in NYC and for Ethicon and for BARD, a free learning experience for you at ultrasoundstore.com. We also install GE, Sonosite, Siemens, Philips, Toshiba, Aloka and every other ultrasound brand, for less, and with in-office training, as we have done for many surgeons at this meeting, through the years.

Toshiba America Medical Systems
An innovator in medical imaging technology, Toshiba America Medical Systems, markets, sells, distributes and services diagnostic imaging systems throughout the United States.  Toshiba is committed to providing our customers with the patient-focused technology and optimum system performance needed to succeed in today’s healthcare marketplace.  From the development of the first electric-scan type ultrasound in 1977 to our landmark shipment of 150,000 ultrasound systems, Toshiba is dedicated to meeting your ultrasound needs whether you are looking for a high-end or an economical system.  Toshiba America Medical Systems is based in Tustin, California.

Vector Surgical
Vector Surgical offers two innovative devices: MarginMarker and CorrectClips.  Invented by a surgeon, MarginMarker and CorrectClips provide a new standard of precision, speed, and safety for tissue orientation.  MarginMarker is a sterile ink kit that accurately delineates the entire margins of excised tissue.  CorrectClips are radiographic clips that feature a letter indicating orientation.

View Exhibitor PDF

Educational Grants

An educational grant for this activity was provided by:


  1. Educational Partners
  2. Genentech BioOncology
  4. Major Contributors
  5. Novartis Oncology
  6. sanofi-aventis U.S.
  8. Supporters
  9. Bristol-Myers Squibb
  10. Eisai, Inc.
  11. ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
  13. Honorary Supporter
  14. Joe’s Stone Crab Restaurant